Skip to main content
Article thumbnail
Location of Repository

Treatment of Peripheral Precocious Puberty

By Melissa Schoelwer and Erica A. Eugster

Abstract

There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available

Topics: peripheral precocious puberty
Publisher: Karger
Year: 2016
DOI identifier: 10.1159/000438895
OAI identifier: oai:scholarworks.iupui.edu:1805/10368
Provided by: IUPUIScholarWorks

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.